Coming soon to the Clinical Genomics Laboratory:
BRCA 1/2 mutational testing
Clinical Genomics Laboratory
Soon to provide BRCA 1/2 mutational testing that looks for changes or mutations in the BRCA1 and BRCA2 genes.
Email us for more information: clinicalgenomicslaboratory@up.edu.ph
Identifies germline mutations in the BRCA 1 and BRCA 2 genes alongside other key mutations involved in hereditary breast and ovarian cancer. It is useful for prognosis, treatment guidance, and screening in high-risk family members for the purposes of cancer prevention and early detection.
(Sample type: blood)
Identifies somatic mutations in the BRCA 1 and BRCA 2 genes alongside other key mutations involved in breast and ovarian cancer. It can help to characterize active cases and provide patients and clinicians with both prognosis and treatment guidance.
(Sample type: formalin-fixed paraffin-embedded tissues)
A clinical multi-omics laboratory
Securing the Future of the Filipino Genome
Ethical
Patient confidentiality, data privacy, and informed consent.
Accessible
Access to quality healthcare should be available to all.
Efficient
Urgency and importance of timely results when it comes to cancer testing.
Advanced
Quick turnaround times without compromising accuracy.
About us
The Philippine Genome Center’s Clinical Genomics Laboratory’s mission is to be the country’s national reference laboratory that will provide ethical, accessible, relevant, efficient, and advanced multi-omics testing services for human health in the Philippines. We will contribute to the body of knowledge in clinical multi-omics diagnostic technologies through our committed and continuous search for innovative platforms for the diagnosis and care of Filipinos. We value the contribution of our clinicians and scientists by providing equitable opportunities for skill-set enhancements and professional growth that will benefit the institution and the country.
The CGL vision is to be a premier national reference multi-omics diagnostic testing center for human health by 2028.
